Presbyopia Epidemiology Forecast

DelveInsight's 'Presbyopia - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Presbyopia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.


Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Study Period: 2017-2030


Presbyopia Understanding

The DelveInsight Presbyopia epidemiology report gives a thorough understanding of the Presbyopia by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Presbyopia in the US, Europe, and Japan. The report covers the detailed information of the Presbyopia epidemiology scenario in seven major countries (US, EU5, and Japan).


Presbyopia Epidemiology Perspective by DelveInsight

The Presbyopia epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Presbyopia epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Presbyopia epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.


Presbyopia Detailed Epidemiology Segmentation

The Presbyopia epidemiology covered in the report provides historical as well as forecasted Presbyopia epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Presbyopia report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.


Scope of the Report

  • The Presbyopia report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Presbyopia Epidemiology Report and Model provide an overview of the risk factors and global trends of Presbyopia in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Presbyopia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Presbyopia
  • The report provides the segmentation of the Presbyopia epidemiology


Report Highlights

  • 11-Year Forecast of Presbyopia epidemiology
  • 7MM Coverage
  • Total Cases of Presbyopia
  • Total Cases of Presbyopia according to segmentation
  • Diagnosed cases of Presbyopia


KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.


Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Presbyopia?
  • What are the key findings pertaining to the Presbyopia epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Presbyopia across the 7MM during the forecast period (2017-2030)?
  •  Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Presbyopia?
  • What are the currently available treatments of Presbyopia?


Reasons to buy

  • The Presbyopia Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Presbyopia market
  • Quantify patient populations in the global Presbyopia market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Presbyopia therapeutics in each of the markets covered
  • Understand the magnitude of Presbyopia population by its epidemiology
  • The Presbyopia Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources


Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights 

2. Executive Summary of Presbyopia

3. Presbyopia: Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Presbyopia Epidemiology Scenario in the 7MM (2017- 2030)

5.4. United States Epidemiology

5.4.1. Presbyopia Epidemiology Scenario in the United States (2017- 2030)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.1.1. Presbyopia Epidemiology Scenario in Germany (2017- 2030)

5.5.2. France Epidemiology

5.5.2.1. Presbyopia Epidemiology Scenario in France (2017- 2030)

5.5.3. Italy Epidemiology

5.5.3.1. Presbyopia Epidemiology Scenario in Italy (2017- 2030)

5.5.4. Spain Epidemiology

5.5.4.1. Presbyopia Epidemiology Scenario in Spain (2017- 2030)

5.5.5. United Kingdom Epidemiology

5.5.5.1. Presbyopia Epidemiology Scenario in the United Kingdom (2017-2030)

5.6. Japan Epidemiology

5.6.1. Presbyopia Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. Presbyopia Treatment and Management

6.2. Presbyopia Treatment Algorithm

7. KOL Views

8. Unmet Needs

9.  Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

*The table of contents is not exhaustive; will be provided in the final report

Table 1  Presbyopia Epidemiology in 7MM (2017-2030)

Table 2 Presbyopia Diagnosed and Treatable Cases in 7MM (2017-2030)

Table 3 Presbyopia Epidemiology in the United States (2017-2030)

Table 4 Presbyopia Diagnosed and Treatable Cases in the United States (2017-2030)

Table 5 Presbyopia Epidemiology in Germany (2017-2030)

Table 6 Presbyopia Diagnosed and Treatable Cases in Germany (2017-2030)

Table 7 Presbyopia Epidemiology in France (2017-2030)

Table 8 Presbyopia Diagnosed and Treatable Cases in France (2017-2030)

Table 9 Presbyopia Epidemiology in Italy (2017-2030)

Table 10 Presbyopia Diagnosed and Treatable Cases in Italy (2017-2030)

Table 11 Presbyopia Epidemiology in Spain (2017-2030)

Table 12 Presbyopia Diagnosed and Treatable Cases in Spain (2017-2030)

Table 13 Presbyopia Epidemiology in the United Kingdom (2017-2030)

Table 14 Presbyopia Diagnosed and Treatable Cases in the United Kingdom (2017-2030)

Table 15 Presbyopia Epidemiology in Japan (2017-2030)

Table 16 Presbyopia Diagnosed and Treatable Cases in Japan (2017-2030)

Figure 1 Presbyopia Epidemiology in 7MM (2017-2030)

Figure 2 Presbyopia Diagnosed and Treatable Cases in 7MM (2017-2030)

Figure 3 Presbyopia Epidemiology in the United States (2017-2030)

Figure 4 Presbyopia Diagnosed and Treatable Cases in the United States (2017-2030)

Figure 5 Presbyopia Epidemiology in Germany (2017-2030)

Figure 6 Presbyopia Diagnosed and Treatable Cases in Germany (2017-2030)

Figure 7 Presbyopia Epidemiology in France (2017-2030)

Figure 8 Presbyopia Diagnosed and Treatable Cases in France (2017-2030)

Figure 9 Presbyopia Epidemiology in Italy (2017-2030)

Figure 10 Presbyopia Diagnosed and Treatable Cases in Italy (2017-2030)

Figure 11 Presbyopia Epidemiology in Spain (2017-2030)

Figure 12 Presbyopia Diagnosed and Treatable Cases in Spain (2017-2030)

Figure 13 Presbyopia Epidemiology in the United Kingdom (2017-2030)

Figure 14 Presbyopia Diagnosed and Treatable Cases in the United Kingdom (2017-2030)

Figure 15 Presbyopia Epidemiology in Japan (2017-2030)

Figure 16 Presbyopia Diagnosed and Treatable Cases in Japan (2017-2030)

*The table of contents is not exhaustive; will be provided in the final report



  • Tags:
  • Presbyopia Epidemiology
  • Presbyopia
  • Presbyopia Pipeline
  • Presbyopia Companies
  • Presbyopia prevalent population
  • Presbyopia incident population
  • Presbyopia patients diagnosed
  • Presbyopia treatment algorithm

Forward to Friend

Need A Quote